FDA grants ODD status to Zai Lab’s lung cancer treatment
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Zai Lab’s delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), ZL-1310, for small cell lung cancer (SCLC).
Zai Lab Gets FDA Orphan Drug Designation For ZL-1310 To Treat Small Cell Lung Cancer
Zai Lab Limited (ZLAB) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation or ODD to ZL-1310, a ...
Le Lézard3d
IMCAS 2025: Galderma's Broad Presence and New Data on Recently Launched Products Restylane® SHAYPEtm and Relfydess® Reaffirm Its Category Leadership
Galderma will present the latest updates from its innovative aesthetics portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2025 on January 30 ? February 1 in Paris, ...
Le Lézard3d
THE FIRST-EVER EIGHT-COUNTRY HOLOCAUST KNOWLEDGE AND AWARENESS INDEX SHOWS GROWING GAP IN KNOWLEDGE ABOUT THE HOLOCAUST, ESPECIALLY IN YOUNG ADULTS
The Conference on Jewish Material Claims Against Germany (Claims Conference) today released the first-ever, eight-country Index on Holocaust Knowledge and Awareness, exposing a global trend in fading ...
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan ...
Stockhouse15d
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
Amado, M.D., President, Head of Global Research and Development at Zai Lab. “Building on the promising findings from our ongoing clinical trials for ZL-1310, this new collaboration demonstrates our ...
Business Wire16d
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
“Building on the promising findings from our ongoing clinical trials for ZL-1310, this new collaboration demonstrates our continued focus on developing cancer therapies with ADC drugs and ...